(MBBS(Hons), BSc(Hons), FFARCSI, FCICM, PGDipEcho)
David is a ;
- Senior Intensive Care Specialist at University Hospital Geelong
- Senior Intensive Care Specialist Critical Care Services at St John of God Hospital Geelong,
- Medical Director of Organ Donation at Barwon Health
- CICM Supervisor of Training, Intensive Care Unit, University Hospital Geelong
He qualified from The Royal College of Surgeons in 1986 and completed Specialist Training in Anaesthesia in Ireland in 1995. Pursuing an Intensive Care Fellowship in Australia he was admitted to the College of Intensive Care Medicine in 1998. Being enamoured of the Australian way of life he became a staff specialist in Geelong in 1998 and an Australian citizen in 2000. He has an interest in all things critical care especially cardiothoracic with qualifications in critical care echo and ECMO. He is also interested in education and training, minimizing patient risk and organ donation.
David holds key roles at UHG in the areas of organ donation, deteriorating patient work, PLS/APLS, and anaesthesia and ICU training.

Medical Director Organ Donation
The Organ and Tissue Authority (OTA) works with states and territories, clinicians and the community sector to deliver the Australian Government’s national reform programme to improve organ and tissue donation and transplantation outcomes in Australia.
Contact DonateLife on 1300 133 050 (toll-free) and learn more about the DonateLife program at http://www.donatelife.gov.au/about-us#sthash.4PdpcnZt.dpuf.
-
Thursday, April 8, 2021 - 16:13
JAMA BACLOREA High-dose baclofen reduced agitation-related events in adult patients with unhealthy alcohol use requiring mechanical ventilation. However secondary outcomes of deeper sedation, longer duration of mechanical ventilation, prolonged ICU care = more research
Tuesday, April 6, 2021 - 14:25JAMA Mechanical ventilation weaning practices vary internationally, regard to the use of protocols, screening for and conducting SBTs, adjustment of ventilator support, and the responsibility of clinicians involved in weaning
Tuesday, April 6, 2021 - 12:01JAMA HENIVOT Trial -Helmet NIV vs HFNC for critically ill patients with mod-severe hypoxemic COVID resp failure = no diff in the resp support fee days (28 d). Secondary diff in intubation, lower in helmet group, ie overall no difference in 28-d resp support, but helmet lower proportion of this time intubated.
Friday, February 19, 2021 - 07:30JAMA RCT does not support use of single high dose oral vitamin D3 for treatment of moderate to severe COVID-19 in hospitalized patients. Limitations in design, however, confirms lack of benefit reported in multiple large non-COVID trials in hospital or ICU patients (VIOLET, VITdAL-ICU)
Sunday, February 14, 2021 - 09:30NEJM DePPaRT: 1% of patients with loss of cardiac activity after planned withdrawal of life sustaining therapy have transient resumption of cardiac activity observable by bedside reports and corroborated by ECG and IABP waveform activity. Retrospective waveform review showed resumption of cardiac activity in 14% of patients. The longest period of pulselessness that was followed by resumption of cardiac activity was 4 minutes 20 seconds.